Management of anticoagulant-related intracranial hemorrhage: An evidence-based review

Critical Care

Volumn 18, Issue 3, 2014, Pages

  Ray, Bappaditya ^a   Keyrouz, Salah G ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTIHYPERTENSIVE AGENT; APIXABAN; ARGATROBAN; DABIGATRAN; ENOXAPARIN; FONDAPARINUX; FRESH FROZEN PLASMA; HEPARIN; HIRULOG; PROTAMINE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; FIBRINOLYTIC THERAPY; HUMAN; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; DISEASE MANAGEMENT; EVIDENCE BASED MEDICINE; INTRACRANIAL HEMORRHAGES; PROCEDURES;

ANTICOAGULANTS; DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; HUMANS; INTRACRANIAL HEMORRHAGES;

EID: 84901376864     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13889     Document Type: Review

References (121)

1. Guyatt GH, Norris SL, Schulman S, Hirsh J, Eckman MH, Akl EA, Crowther M, Vandvik PO, Eikelboom JW, McDonagh MS, Lewis SZ, Gutterman DD, Cook DJ, Schunermann HJ. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:53S-70S. 10.1378/chest.11-2288, 3278053, 22315256.
2. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Vergeut FW, Weitz JI. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol 2012, 59:1413-1425. 10.1016/j.jacc.2012.02.008, 22497820.
3. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Vergeut FW, Weitz JI. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013, 109:569-579. 10.1160/TH12-10-0772, 23447024.
4. Stroke Prevention in Atrial Fibrillation Invesitgators group Stroke prevention in atrial fibrillation study. Final results. Circulation 1991, 84:527-539. Stroke Prevention in Atrial Fibrillation Invesitgators group.
5. European Atrial Fibrillation Trial Study Group Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993, 342:1255-1262. European Atrial Fibrillation Trial Study Group.
6. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med 1996, 156:2537-2541. 10.1001/archinte.1996.00440210043004, 8951296.
7. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285:2370-2375. 10.1001/jama.285.18.2370, 11343485.
8. Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, Moomaw CJ, Haverbusch M, Broderick JP. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 2007, 68:116-121. 10.1212/01.wnl.0000250340.05202.8b, 17210891.
9. Kase CS, Robinson RK, Stein RW, DeWitt LD, Hier DB, Harp DL, Williams JP, Caplan LR, Mohr JP. Anticoagulant-related intracerebral hemorrhage. Neurology 1985, 35:943-948. 10.1212/WNL.35.7.943, 4010961.
10. Kase CS. Intracerebral hemorrhage: non-hypertensive causes. Stroke 1986, 17:590-595. 10.1161/01.STR.17.4.590, 3526643.
11. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995, 26:1471-1477. 10.1161/01.STR.26.8.1471, 7631356.
12. Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke 2006, 37:256-262. 10.1161/01.STR.0000196989.09900.f8, 16339459.
13. Franke CL, de Jonge J, van Swieten JC, Op de Coul AA, van Gijn J. Intracerebral hematomas during anticoagulant treatment. Stroke 1990, 21:726-730. 10.1161/01.STR.21.5.726, 2339452.
14. Wintzen AR, de Jonge H, Loeliger EA, Bots GT. The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study. Ann Neurol 1984, 16:553-558. 10.1002/ana.410160505, 6508238.
15. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Internal Med 1994, 120:897-902.
16. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989, 87:144-152. 10.1016/S0002-9343(89)80689-8, 2787958.
17. Barron KD, Fergusson G. Intracranial hemorrhage as a complication of anticoagulant therapy. Neurology 1959, 9:447-455. 10.1212/WNL.9.7.447, 13666927.
18. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrom SZ, Poulsen HE, Kober L, Torp-Pedesen C. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010, 170:1433-1441.
19. Radberg JA, Olsson JE, Radberg CT. Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment. Stroke 1991, 22:571-576. 10.1161/01.STR.22.5.571, 2028484.
20. Hart RG, Pearce LA. In vivo antithrombotic effect of aspirin: dose versus nongastrointestinal bleeding. Stroke 1993, 24:138-139.
21. Smith EE, Rosand J, Knudsen KA, Hylek EM, Greenberg SM. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology 2002, 59:193-197. 10.1212/WNL.59.2.193, 12136056.
22. Snyder M, Renaudin J. Intracranial hemorrhage associated with anticoagulation therapy. Surg Neurol 1977, 7:31-34.
23. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol 1997, 42:857-865. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group.
24. International Stroke Trial Collaborative Group The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997, 349:1569-1581. International Stroke Trial Collaborative Group.
25. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA 1998, 279:1265-1272. 10.1001/jama.279.16.1265, 9565006, The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators.
26. LaMonte MP, Nash ML, Wang DZ, Woolfenden AR, Schultz J, Hursting MJ, Brown PM. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke 2004, 35:1677-1682. 10.1161/01.STR.0000131549.20581.ba, 15155959.
27. Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, Ezekowitz MD, Yusuf S. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012, 43:1511-1517. 10.1161/STROKEAHA.112.650614, 22492518.
28. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342-2352. 10.1056/NEJMoa0906598, 19966341.
29. Flaker GC, Eikelboom JW, Shestakovska O, Connolly SJ, Kaatz S, Budaj A, Husted S, Yusuf S, Lip GY, Hart RG. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial. Stroke 2012, 43:3291-3297. 10.1161/STROKEAHA.112.664144, 23033347.
30. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992. 10.1056/NEJMoa1107039, 21870978.
31. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891. 10.1056/NEJMoa1009638, 21830957.
32. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012, 366:1287-1297.
33. Wayangankar SA, Abu-Fadel MS, Aronow HD, Kennedy KF, Gupta R, Yeh RW, Gray WA, Rosenfield K, Hennebry TA. Hemorrhagic and ischemic outcomes after bivalirudin versus unfractionated heparin during carotid artery stenting: a propensity score analysis from the NCDR. Circ Cardiovasc Interv 2013, 6:131-138. 10.1161/CIRCINTERVENTIONS.112.974857, 23532554.
34. Flaherty ML, Haverbusch M, Sekar P, Kissela BM, Kleindorfer D, Moomaw CJ, Broderick JP, Woo D. Location and outcome of anticoagulant-associated intracerebral hemorrhage. Neurocrit Care 2006, 5:197-201. 10.1385/NCC:5:3:197, 17290088.
35. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004, 164:880-884. 10.1001/archinte.164.8.880, 15111374.
36. Sjalander A, Engstrom G, Berntorp E, Svensson P. Risk of haemorrhagic stroke in patients with oral anticoagulation compared with the general population. J Intern Med 2003, 254:434-438. 10.1046/j.1365-2796.2003.01209.x, 14535964.
37. Flaherty ML, Tao H, Haverbusch M, Sekar P, Kleindorfer D, Kissela B, Khatri P, Stettler B, Adeoye O, Moomaw CJ, Broderick JP, Woo D. Warfarin use leads to larger intracerebral hematomas. Neurology 2008, 71:1084-1089. 10.1212/01.wnl.0000326895.58992.27, 2668872,2668872, 18824672.
38. Flaherty ML. Anticoagulant-associated intracerebral hemorrhage. Semin Neurol 2010, 30:565-572. 10.1055/s-0030-1268866, 21207349.
39. Cucchiara B, Messe S, Sansing L, Kasner S, Lyden P. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke 2008, 39:2993-2996. 10.1161/STROKEAHA.108.520668, 18703803.
40. Dowlatshahi D, Butcher KS, Asdaghi N, Nahirniak S, Bernbaum ML, Giulivi A, Wasserman JK, Poon MC, Coutts SB. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke 2012, 43:1812-1817. 10.1161/STROKEAHA.112.652065, 22556194.
41. Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Moia M, Palareti G, Poli D, Testa S, Tiraferri E, Tosetto A, Tripodi A, Siragusa S, Manotti C. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. J Thromb Haemost 2012, 10:1979-1987. 10.1111/j.1538-7836.2012.04866.x, 22827490.
42. Levy JH, Dutton RP, Hemphill JC, Shander A, Cooper D, Paidas MJ, Kessler CM, Holcomb JB, Lawson JH. Multidisciplinary approach to the challenge of hemostasis. Anesth Analg 2010, 110:354-364. 10.1213/ANE.0b013e3181c84ba5, 20007735.
43. Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 2008, 111:4871-4879. 10.1182/blood-2007-10-120543, 18309033.
44. Steiner T, Bohm M, Dichgans M, Diener HC, Ell C, Endres M, Epple C, Grond M, Laufs U, Nickenig G, Reiss H, Rother J, Schellinger PD, Spannagl M, Veltkamp R. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 2013, 102:399-412. 10.1007/s00392-013-0560-7, 23669868.
45. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124:1573-1579. 10.1161/CIRCULATIONAHA.111.029017, 21900088.
46. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010, 103:1116-1127. 10.1160/TH09-11-0758, 20352166.
47. Yuan S, Ferrell C, Chandler WL. Comparing the prothrombin time INR versus the APTT to evaluate the coagulopathy of acute trauma. Thromb Res 2007, 120:29-37. 10.1016/j.thromres.2006.07.002, 16887171.
48. Tripodi A. The laboratory and the new oral anticoagulants. Clin Chem 2013, 59:353-362. 10.1373/clinchem.2012.189704, 23043068.
49. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor. Thromb Haemost 2010, 103:815-825. 10.1160/TH09-03-0176, 20135059.
50. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007, 64:292-303. 10.1111/j.1365-2125.2007.02899.x, 2000643, 17506785.
51. Chandler WL. Emergency assessment of hemostasis in the bleeding patient. Int J Lab Hematol 2013, 35:339-343. 10.1111/ijlh.12071, 23480055.
52. Chandler WL. The thromboelastography and the thromboelastograph technique. Semin Thromb Hemost 1995, 21:1-6. 10.1055/s-2007-1000374, 8747681.
53. Cotton BA, Faz G, Hatch QM, Radwan ZA, Podbielski J, Wade C, Kozar RA, Holcomb JB. Rapid thrombelastography delivers real-time results that predict transfusion within 1 hour of admission. J Trauma 2011, 71:407-414. discussion 414-417, 10.1097/TA.0b013e31821e1bf0, 21825945.
54. Gorlinger K, Dirkmann D, Hanke AA, Kamler M, Kottenberg E, Thielmann M, Jakob H, Peters J. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. Anesthesiology 2011, 115:1179-1191.
55. Neyens R, Bohm N, Cearley M, Andrews C, Chalela J. Dabigatran-associated subdural hemorrhage: using thromboelastography (TEG) to guide decision-making. J Thromb Thrombolysis 2014, 37:80-83. 10.1007/s11239-013-0933-9, 23666496.
56. Ammollo CT, Semeraro F, Incampo F, Semeraro N, Colucci M. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2010, 8:790-798. 10.1111/j.1538-7836.2010.03739.x, 20088944.
57. Selim MH, Molina CA. The role of hemostatic therapy in anticoagulation-associated intracerebral hemorrhage: intuition versus evidence. Stroke 2012, 43:2539-2540. 10.1161/STROKEAHA.111.648840, 22811463.
58. Rosand J, Hylek EM, O'Donnell HC, Greenberg SM. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology 2000, 55:947-951. 10.1212/WNL.55.7.947, 11061249.
59. Appelboam R, Thomas EO. Warfarin and intracranial haemorrhage. Blood Rev 2009, 23:1-9. 10.1016/j.blre.2008.05.001, 18583002.
60. Punthakee X, Doobay J, Anand SS. Oral-anticoagulant-related intracerebral hemorrhage. Thromb Res 2002, 108:31-36. 10.1016/S0049-3848(02)00398-5, 12586129.
61. Wijdicks EF, Schievink WI, Brown RD, Mullany CJ. The dilemma of discontinuation of anticoagulation therapy for patients with intracranial hemorrhage and mechanical heart valves. Neurosurgery 1998, 42:769-773. 10.1097/00006123-199804000-00053, 9574641.
62. Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE. A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001, 115:145-149. 10.1046/j.1365-2141.2001.03070.x, 11722425.
63. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133:160S-198S. 10.1378/chest.08-0670, 18574265.
64. Steiner T, Kaste M, Forsting M, Mendelow D, Kwiecinski H, Szikora I, Juvela S, Marchel A, Chapot R, Cognard C, Unterberg A, Hacke W. Recommendations for the management of intracranial haemorrhage - part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis 2006, 22:294-316.
65. Hellstern P, Muntean W, Schramm W, Seifried E, Solheim BG. Practical guidelines for the clinical use of plasma. Thromb Res 2002, 107:S53-S57.
66. Lee SB, Manno EM, Layton KF, Wijdicks EF. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology 2006, 67:1272-1274. 10.1212/01.wnl.0000238104.75563.2f, 17030765.
67. Goodnough LT, Shander A. How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. Blood 2011, 117:6091-6099. 10.1182/blood-2010-11-316075, 21411756.
68. Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost 2007, 98:790-797.
69. Hanley JP. Warfarin reversal. J Clin Pathol 2004, 57:1132-1139. 10.1136/jcp.2003.008904, 1770479, 15509671.
70. Schulman S. Clinical practice. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003, 349:675-683. 10.1056/NEJMcp025373, 12917305.
71. Sarode R, Milling TJ, Refaai MA, Mangione A, Schneider A, Durn BL, Goldstein JN. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013, 128:1234-1243.
72. Wojcik C, Schymik ML, Cure EG. Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J Emerg Med 2009, 2:217-225. 10.1007/s12245-009-0125-8, 2840588, 20436891.
73. Sorensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity. Crit Care 2011, 15:201. 10.1186/cc9311, 3222012, 21345266.
74. Dentali F, Marchesi C, Pierfranceschi MG, Crowther M, Garcia D, Hylek E, Witt DM, Clark NP, Squizzato A, Imberti D, Ageno W. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 2011, 106:429-438. 10.1160/TH11-01-0052, 21800002.
75. Guest JF, Watson HG, Limaye S. Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United kingdom. Clin Ther 2010, 32:2478-2493. 10.1016/j.clinthera.2011.01.011, 21353116.
76. Huttner HB, Schellinger PD, Hartmann M, Kohrmann M, Juettler E, Wikner J, Mueller S, Meyding-Lamade U, Strobl R, Mansmann U, Schwab S, Steiner T. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006, 37:1465-1470. 10.1161/01.STR.0000221786.81354.d6, 16675739.
77. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997, 77:477-480.
78. Sjoblom L, Hardemark HG, Lindgren A, Norrving B, Fahlen M, Samuelsson M, Stigendal L, Stockelberg D, Taghavi A, Wallrup L, Wallvik J. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke 2001, 32:2567-2574. 10.1161/hs1101.098523, 11692018.
79. Steiner T, Freiberger A, Griebe M, Husing J, Ivandic B, Kollmar R, Pfefferkorn T, Wartenberg KE, Weimar C, Hennerici M, Poli S. International normalised ratio normalisation in patients with coumarin-related intracranial haemorrhages - the INCH trial: a randomised controlled multicentre trial to compare safety and preliminary efficacy of fresh frozen plasma and prothrombin complex - study design and protocol. Int J Stroke 2011, 6:271-277. 10.1111/j.1747-4949.2010.00560.x, 21557816.
80. Tawil IS, DB, Duprey J. Emergency management of coagulopathy in acute intracranial hemorrhage. EM Crit Care 2012, 2:1-20.
81. Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012, 108:217-224. 10.1160/TH12-03-0179, 22627883.
82. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Internal Med 2002, 137:884-888.
83. Hedner U, Erhardtsen E. Potential role of recombinant factor VIIa as a hemostatic agent. Clin Adv Hematol Oncol 2003, 1:112-119.
84. Dager WE, King JH, Regalia RC, Williamson D, Gosselin RC, White RH, Tharratt RS, Albertson TE. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy 2006, 26:1091-1098. 10.1592/phco.26.8.1091, 16863486.
85. Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003, 14:469-477. 10.1097/00001721-200307000-00007, 12851533.
86. Gabriel DA, Carr M, Roberts HR. Monitoring coagulation and the clinical effects of recombinant factor VIIa. Semin Hematol 2004, 41:20-24.
87. Levi M, Bijsterveld NR, Keller TT. Recombinant factor VIIa as an antidote for anticoagulant treatment. Semin Hematol 2004, 41:65-69.
88. Tanaka KA, Szlam F, Dickneite G, Levy JH. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. Thromb Res 2008, 122:117-123. 10.1016/j.thromres.2007.09.002, 17977586.
89. Bijsterveld NR, Moons AH, Boekholdt SM, van Aken BE, Fennema H, Peters RJ, Meijers JC, Buller HR, Levi M. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002, 106:2550-2554. 10.1161/01.CIR.0000038501.87442.02, 12427650.
90. Kase CS, Greenberg SM, Mohr JP, Caplan LR. Intracerebral Hemorrhage. Stroke: Pathophysiology, Diagnosis, and Management 2011, 531-588. Philadelphia, PA: Elsevier Saunders, Mohr JP.
91. Holst J, Lindblad B, Bergqvist D, Garre K, Nielsen H, Hedner U, Ostergaard PB. Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in healthy volunteers. Blood Coagul Fibrinolysis 1994, 5:795-803. 10.1097/00001721-199410000-00018, 7865687.
92. Liu-DeRyke X, Rhoney D. Hemostatic therapy for the treatment of intracranial hemorrhage. Pharmacotherapy 2008, 28:485-495. 10.1592/phco.28.4.485, 18363532.
93. Sorimachi T, Fujii Y, Morita K, Tanaka R. Rapid administration of antifibrinolytics and strict blood pressure control for intracerebral hemorrhage. Neurosurgery 2005, 57:837-844. 10.1227/01.NEU.0000180815.38967.57, 16284553.
94. Illanes S, Zhou W, Schwarting S, Heiland S, Veltkamp R. Comparative effectiveness of hemostatic therapy in experimental warfarin-associated intracerebral hemorrhage. Stroke 2011, 42:191-195. 10.1161/STROKEAHA.110.593541, 21127298.
95. Alikhan R, Rayment R, Keeling D, Baglin T, Benson G, Green L, Marshall S, Patel R, Pavord S, Rose P, Tait C. The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emerg Med J 2014, 31:163-168. 10.1136/emermed-2012-201976, 3913117, 23435652.
96. French KF, White J, Hoesch RE. Treatment of intracerebral hemorrhage with tranexamic acid after thrombolysis with tissue plasminogen activator. Neurocrit Care 2012, 17:107-111. 10.1007/s12028-012-9681-5, 22311234.
97. Lu G, Deguzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013, 19:446-451. 10.1038/nm.3102, 23455714.
98. Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T. A specific antidote for dabigatran: functional and structural characterization. Blood 2013, 121:3554-3562. 10.1182/blood-2012-11-468207, 23476049.
99. Kaatz S, Crowther M. Reversal of target-specific oral anticoagulants. J Thromb Thrombolysis 2013, 36:195-202. 10.1007/s11239-013-0923-y, 23657589.
100. Khoo TL, Weatherburn C, Kershaw G, Reddel CJ, Curnow J, Dunkley S. The use of FEIBA(R) in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol 2013, 35:222-224. 10.1111/ijlh.12005, 23020832.
101. Johnson & Johnson Pharmaceutical Research & Development LLC Advisory Committee Briefing Book: Rivaroxaban for the Prophylaxis of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Patients Undergoing Hip or Knee Replacement Surgery 2009, San Diego, CA: Johnson & Johnson Pharmaceutical Research & Development, L.L.C, Johnson & Johnson Pharmaceutical Research & Development LLC.
102. Eliquis - Apixaban. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002148/human_med_001449.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125.
103. Khadzhynov D, Wagner F, Formella S, Wiegert E, Moschetti V, Slowinski T, Neumayer HH, Liesenfeld KH, Lehr T, Hartter S, Friedman J, Peters H, Clemens A. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 2013, 109:596-605. 10.1160/TH12-08-0573, 23389759.
104. Van Ryn J, Neubauer M, Flieg R, Krause B, Storr M, Hauel N, Priepke H, Clemens A. Successful removal of dabigatran in flowing blood with an activated charcoal hemoperfusion column in an in vitro test system. Haematologica 2010, 95:293. 10.3324/haematol.2009.013318, 2817033, 20139392.
105. Morgenstern LB, Hemphill JC, Anderson C, Becker K, Broderick JP, Connolly ES, Greenberg SM, Huang JN, MacDonald RL, Messe SR, Mitchell PH, Selim M, Tamago RJ. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010, 41:2108-2129. 10.1161/STR.0b013e3181ec611b, 20651276.
106. Qureshi AI, Palesch YY, Martin R, Novitzke J, Cruz-Flores S, Ehtisham A, Ezzeddine MA, Goldstein JN, Hussein HM, Suri MF, Tariq N. Effect of systolic blood pressure reduction on hematoma expansion, perihematomal edema, and 3-month outcome among patients with intracerebral hemorrhage: results from the antihypertensive treatment of acute cerebral hemorrhage study. Arch Neurol 2010, 67:570-576. 10.1001/archneurol.2010.61, 20457956.
107. Zhang Y, Reilly KH, Tong W, Xu T, Chen J, Bazzano LA, Qiao D, Ju Z, Chen CS, He J. Blood pressure and clinical outcome among patients with acute stroke in Inner Mongolia, China. J Hypertens 2008, 26:1446-1452. 10.1097/HJH.0b013e328300a24a, 18551022.
108. Powers WJ, Zazulia AR, Videen TO, Adams RE, Yundt KD, Aiyagari V, Grubb RL, Diringer MN. Autoregulation of cerebral blood flow surrounding acute (6 to 22 hours) intracerebral hemorrhage. Neurology 2001, 57:18-24. 10.1212/WNL.57.1.18, 11445622.
109. Zazulia AR, Diringer MN, Videen TO, Adams RE, Yundt K, Aiyagari V, Grubb RL, Powers WJ. Hypoperfusion without ischemia surrounding acute intracerebral hemorrhage. J Cereb Blood Flow Metab 2001, 21:804-810.
110. Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, Lindley R, Robinson T, Lavados P, Neal B, Hata J, Arima H, Parsons M, Li Y, Wang J, Heritier S, Li Q, Woodward M, Simes RJ, Davis SM, Chalmers J, . INTERACT2 Investigators Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013, 368:2355-2365. 10.1056/NEJMoa1214609, 23713578, INTERACT2 Investigators.
111. Qureshi AI, Palesch YY. Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II: design, methods, and rationale. Neurocrit Care 2011, 15:559-576. 10.1007/s12028-011-9538-3, 3340125, 21626077.
112. Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, Karimi A, Shaw MD, Barer DH. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005, 365:387-397. 10.1016/S0140-6736(05)17826-X, 15680453.
113. Mendelow AD, Gregson BA, Rowan EN, Murray GD, Gholkar A, Mitchell PM, . STICH II Investigators Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. Lancet 2013, 382:397-408. 10.1016/S0140-6736(13)60986-1, 3906609, 23726393, STICH II Investigators.
114. Bullock MR, Chesnut R, Ghajar J, Gordon D, Hartl R, Newell DW, Servadei F, Walters BC, Wilberger JE. Surgical management of acute subdural hematomas. Neurosurgery 2006, 58:S16-S24. discussion Si-Siv.
115. Bullock MR, Chesnut R, Ghajar J, Gordon D, Hartl R, Newell DW, Servadei F, Walters BC, Wilberger JE. Surgical management of acute epidural hematomas. Neurosurgery 2006, 58:S7-S15. discussion Si-Siv.
116. Senft C, Schuster T, Forster MT, Seifert V, Gerlach R. Management and outcome of patients with acute traumatic subdural hematomas and pre-injury oral anticoagulation therapy. Neurol Res 2009, 31:1012-1018. 10.1179/174313209X409034, 19570326.
117. Lee SH, Ryu WS, Roh JK. Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage. Neurology 2009, 72:171-176. 10.1212/01.wnl.0000339060.11702.dd, 19139370.
118. Claassen DO, Kazemi N, Zubkov AY, Wijdicks EF, Rabinstein AA. Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage. Arch Neurol 2008, 65:1313-1318.
119. Majeed A, Kim YK, Roberts RS, Holmstrom M, Schulman S. Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke 2010, 41:2860-2866. 10.1161/STROKEAHA.110.593087, 21030703.
120. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994, 89:635-641. 10.1161/01.CIR.89.2.635, 8313552.
121. Steiner T. Resumption of oral anticoagulation after warfarin-associated intracerebral hemorrhage: yes. Stroke 2011, 42:3661-3662. 10.1161/STROKEAHA.111.621797, 22052514.